<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Mycophenolate mofetil</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00688</strong>&#160; (APRD01602)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (<span class="caps">MPA</span>), an immunosuppressive agent, inosine monophosphate dehydrogenase (<span class="caps">IMPDH</span>) inhibitor.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00688/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00688/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00688.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00688.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00688.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00688.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00688.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00688">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>MMF</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>CellCept</td><td>Genentech USA, Inc.</td></tr><tr><td>CellCept  Oral Suspension </td><td>Genentech USA, Inc.</td></tr><tr><td>CellCept Intravenous</td><td>Genentech USA, Inc.</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>128794-94-5</td></tr><tr><th>Weight</th><td>Average: 433.4947<br>Monoisotopic: 433.210052351</td></tr><tr><th>Chemical Formula</th><td>C<sub>23</sub>H<sub>31</sub>NO<sub>7</sub></td></tr><tr><th>InChI Key</th><td>RTGDFNSFWBGLEC-SYZQJQIISA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzofurans</td></tr><tr><th>Subclass</th><td>Benzofuranones</td></tr><tr><th>Direct parent</th><td>Phthalides</td></tr><tr><th>Alternative parents</th><td>Hydroxybenzoic Acid Derivatives; Methoxyphenols and Derivatives; Anisoles; Para Cresols; Fatty Acid Esters; Alkyl Aryl Ethers; Toluenes; Morpholines; Dicarboxylic Acids and Derivatives; Carboxylic Acid Esters; Tertiary Amines; Enolates; Dialkyl Ethers; Enols; Polyamines</td></tr><tr><th>Substituents</th><td>p-cresol; anisole; phenol ether; alkyl aryl ether; fatty acid ester; phenol derivative; toluene; oxazinane; benzene; morpholine; dicarboxylic acid derivative; carboxylic acid ester; tertiary amine; enol; ether; polyamine; dialkyl ether; enolate; carboxylic acid derivative; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the phthalides. These are compounds containing a 3-hydrocarbylidene-2-benzofuran-1(3H)-one moiety,.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids. </td></tr><tr><th>Pharmacodynamics</th><td>Mycophenolate mofetil is a prodrug of mycophenolic acid (MPA), an antibiotic substance derived from <i>Penicillium stoloniferum</i>. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.</td></tr><tr><th>Mechanism of action</th><td>Mycophenolate mofetil is hydrolyzed to form mycophenolic acid (MPA), which is the active metabolite. MPA is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways, MPA has potent cytostatic effects on lymphocytes. MPA inhibits proliferative responses of T- and B-lymphocytes to both mitogenic and allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the cytostatic effects of MPA on lymphocytes. MPA also suppresses antibody formation by B-lymphocytes. MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. Mycophenolate mofetil did not inhibit early events in the activation of human peripheral blood mononuclear cells, such as the production of interleukin-1 (IL-1) and interleukin-2 (IL-2), but did block the coupling of these events to DNA synthesis and proliferation.</td></tr><tr><th>Absorption</th><td>Rapidly absorbed following oral administration. In 12 healthy volunteers, the mean absolute bioavailability of oral mycophenolate mofetil relative to intravenous mycophenolate mofetil (based on MPA AUC) was 94%. The absolute bioavailability of the delayed release tablet in stable renal transplant patients on cyclosporin is 72%. Food (27 g fat, 650 calories) has no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>3.6 &#177;1.5 L/kg [intravenous, healthy subjects, <span class="caps">MPA</span>]</li>
	<li>4 &#177;1.2 L/kg [oral administration, healthy subjects, <span class="caps">MPA</span>]</li>
</ul></td></tr><tr><th>Protein binding</th><td>MPA (the active metabolite), at clinically relevant concentrations, is over 98% bound to plasma albumin. The phenolic glucuronide of MPA, mycophenolic acid glucuronide  (MPAG) has 82% protein bound. </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Following oral and intravenous dosing, mycophenolate mofetil undergoes complete metabolism to MPA, the active metabolite. Metabolism to MPA occurs presystemically after oral dosing. MPA is metabolized principally by glucuronyl transferase to form the phenolic glucuronide of MPA (MPAG) which is not pharmacologically active. In vivo, MPAG is converted to MPA via enterohepatic recirculation. The following metabolites of the 2-hydroxyethyl-morpholino moiety are also recovered in the urine following oral administration of mycophenolate mofetil to healthy subjects: N-(2-carboxymethyl)-morpholine, N-(2-hydroxyethyl)-morpholine, and the N-oxide of N-(2-hydroxyethyl)-morpholine. Cytochrome P450 isozymes, CYP3A4/5 and to a lesser extent by CYP2C8, is responsible for the biotransformation of MPA to 6-O-desmethyl-mycophenolic acid. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Mycophenolate mofetil</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00629">Mycophenolic acid (MPA)</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/649">Details</a></td></tr><tr><td>Mycophenolate mofetil</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00916">Mycophenolic acid glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/937">Details</a></td></tr><tr><td>Mycophenolate mofetil</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00918">N-(2-carboxymethyl)-morpholine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/939">Details</a></td></tr><tr><td>Mycophenolate mofetil</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00919">N-(2-hydroxyethyl)-morpholine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/940">Details</a></td></tr><tr><td>Mycophenolate mofetil</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00920">N-(2-hydroxyethyl)-morpholine N-oxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/941">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Negligible amount of drug is excreted as MPA (</td></tr><tr><th>Half life</th><td>The mean elimination half-life for mycophenolic acid (the active metabolite) ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.</td></tr><tr><th>Clearance</th><td><ul>
	<li>193 mL/min [plasma clearance, <span class="caps">MPA</span>, oral administration]</li>
	<li>177 mL/min [plasma clearance, <span class="caps">MPA</span>, IV administration]</li>
	<li>15.5 mL/min [renal clearance, <span class="caps">MPAG</span>, delayed-release tablet]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and &gt;6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Mycophenolic Acid Metabolism Pathway</td><td>Drug metabolism</td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8938</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8594</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.5904</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8908</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8381</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8061</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5379</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8528</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.602</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7646</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6878</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9155</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7684</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9122</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8316</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8664</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6484
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.953
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.658
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.0412 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Strong inhibitor 
        </td>
        <td>
            0.771
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7653
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Roche palo alto llc</li>
<li>Accord healthcare inc usa</li>
<li>Apotex corp</li>
<li>Endo pharmaceuticals inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Roxane laboratories inc</li>
<li>Sandoz inc</li>
<li>Strides arcolab ltd</li>
<li>Teva pharmaceuticals usa</li>
<li>Zydus pharmaceuticals usa inc</li>
<li>Accord healthcare inc</li>
<li>Apotex inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.accord-healthcare.com">Accord Healthcare</a></li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li>Cadila Healthcare Ltd.</li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.ccsb.com.tw">Chunghwa Chemical Synthesis and Biotech Co. Ltd.</a></li>
<li><a href="http://www.endo.com">Endo Pharmaceuticals Inc.</a></li>
<li><a href="http://www.roche.com">F Hoffmann La Roche Ltd.</a></li>
<li><a href="http://www.roche.com">F Hoffmann-La Roche Ltd.</a></li>
<li><a href="http://www.intaspharma.com">Intas Pharmaceuticals Ltd.</a></li>
<li><a href="http://www.jhppharma.com">JHP Pharmaceuticals LLC</a></li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.legacypackaging.com">Legacy Pharmaceuticals Packaging LLC</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.poli.it">Poli Industria Chimica SPA</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.syntexar.com">Syntex SA</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>250 mg</td></tr><tr><td>Injection, powder, for solution</td><td>Intravenous</td><td>500 mg</td></tr><tr><td>Suspension</td><td>Oral</td><td>200 mg/mL</td></tr><tr><td>Tablet</td><td>Oral</td><td>500 mg</td></tr><tr><td>Tablet, delayed release</td><td>Oral</td><td>180 mg, 360 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06681">Belatacept</a></td><td>Belatacept increases the Cmax and AUC of mycophenolate mofetil. </td></tr><tr><td><a href="/drugs/DB01373">Calcium</a></td><td>Formation of non-absorbable complexes</td></tr><tr><td><a href="/drugs/DB01592">Iron</a></td><td>Oral iron decreases the absorption of mycophenolate-mofetil</td></tr><tr><td><a href="/drugs/DB00893">Iron Dextran</a></td><td>Oral iron decreases the absorption of mycophenolate-mofetil</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the serum concentration of mycophenolate. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB06372">Rilonacept</a></td><td>results in increased immunosuppressive effects; increases the risk of infection. </td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Tacrolimus may increase the plasma concentration of Mycophenolic acid. Monitor and adjust the dose of Mycophenolate mofetil to the therapeutic range.</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.</td></tr><tr><td><a href="/drugs/DB01610">Valganciclovir</a></td><td>The excretion rates of Valganciclovir and/or Mycophenolate mofetil may decrease. Monitor for increased serum concentrations and toxicity of both agents.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication.</li>
<li>Take on empty stomach: 1 hour before or 2 hours after meals.</li></ul></td></tr></tbody></table>